About 

オプションチェーンは、Universe Pharmaceuticalsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Universe Pharmaceuticalsの市場センチメントを評価します。.

Universe Pharmaceuticals (NASDAQ:UPC) 株価情報, オプションチェーン

Universe Pharmaceuticals

Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.

Universe Pharmaceuticals Inc - Ordinary Shares

Universe Pharmaceuticals Inc

UNI-PRESIDENT C/H UNS/ADR by Uni-President China Holdings Ltd.

Uni-President China Holdings Ltd

UNIVERSAL POTASH CORP by Universal Potash Corp.

Universal Potash Corp

News

Financing

Humana Enters Into $5B Unsecured Revolving Credit Agreement; Agreement Permits Up To $1B Of Incremental Commitments; New Agreement Replaces Existing $2.1B Credit Agreement

Management

Color Star Technology Co Louis Luo Resigned From His Position As Ceo; Samantha Huang Appointed As Ceo

Offerings

SIEB

Siebert Financial Files For Mixed Shelf Of Up To $100M

<ul>
<li>The Generation Essentials Group and Black Spade Acquisition II Co Expect to Close the Business Combination on June 3, 2025.</li>
<li>TGE's Class A Ordinary Shares and Warrants are Expected to Be Listed on the New York Stock Exchange and NYSE American under Ticker Symbols "TGE" and "TGEWS", Respectively, Shortly After the Closing of the Business Combination, on a Date to be Announced.</li>
</ul>
The Generation Essentials Group ("TGE") and Black Spade Acquisition II Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSII#NASDAQ">BSII</a>) ("Black Spade II") today announced that their previously announced business combination (the "Business Combination") was approved at an extraordinary general meeting of Black Spade II's shareholders on May 30, 2025.
Complete official results of the vote will be included in a current report on Form 8-K to be filed by Black Spade II with the U.S. Securities and Exchange Commission.
The Business Combination is expected to close on June 3, 2025. Upon such closing, TGE will remain as the combined company, and its Class A ordinary shares and warrants are expected to be listed on the New York Stock Exchange and NYSE American under the ticker symbols "TGE" and "TGEWS", respectively, shortly thereafter, on a date to be announced.

BSII

Generation Essentials Group And Black Spade Acquisition II Co Set To Close Business Combination On June 3, 2025; TGE Shares To Trade On NYSE Under Ticker Symbol "TGE" Following Closing

General

DIST

Distoken Acquisition Corp Enters Business Combination Agreement With Youlife Group

Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) reported quarterly losses of $(1.19) per share which missed the analyst consensus estimate of $(0.25) by 376 percent. This is a 58.67 percent decrease over losses of $(0.75) per share from the same period last year. The company reported quarterly sales of $1.06 million which missed the analyst consensus estimate of $1.48 million by 28.61 percent. This is a 36.85 percent decrease over sales of $1.68 million the same period last year.

Earnings

Earnings Misses

PSTV

Plus Therapeutics Q1 EPS $(1.19) Misses $(0.25) Estimate, Sales $1.06M Miss $1.48M Estimate

TVRD

Tvardi Therapeutics Files Prospectus Relates To Resale By Selling Stockholders Of Up To 2.1M Shares Of Common Stock

CNFR

Conifer Holdings Receives $10M Contingent Payment

MSGM

Motorsport Games Files Prospectus Related To Resale From Time To Time Of Up To 2.3M Shares Of Class A Common Stock By Selling Stockholders

Copart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRT#NASDAQ">CPRT</a>) has outperformed the market over the past 20 years by 10.62% on an annualized basis producing an average annual return of 18.9%. Currently, Copart has a market capitalization of $49.73 billion. 
Buying $1000 In CPRT: If an investor had bought $1000 of CPRT stock 20 years ago, it would be worth $31,802.32 today based on a price of $51.48 for CPRT at the time of writing.
<h3>Copart's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748636153_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

CPRT

$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Financial giants have made a conspicuous bearish move on Coinbase Global. Our analysis of options history for Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) revealed 53 unusual trades.
Delving into the details, we found 30% of traders were bullish, while 54% showed bearish tendencies. Out of all the trades we spotted, 23 were puts, with a value of $1,333,317, and 30 were calls, valued at $2,194,271.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $135.0 to $690.0 for Coinbase Global over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Coinbase Global's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Coinbase Global's significant trades, within a strike price range of $135.0 to $690.0, over the past month.
<h3>Coinbase Global Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748635849_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>COIN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/17/27</td>
<td>$195.45</td>
<td>$193.0</td>
<td>$193.0</td>
<td>$400.00</td>
<td>$289.5K</td>
<td>15</td>
<td>15</td>
</tr>
<tr>
<td>COIN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$9.3</td>
<td>$8.8</td>
<td>$9.0</td>
<td>$320.00</td>
<td>$270.0K</td>
<td>1.0K</td>
<td>321</td>
</tr>
<tr>
<td>COIN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/06/25</td>
<td>$3.1</td>
<td>$3.0</td>
<td>$3.0</td>
<td>$260.00</td>
<td>$153.9K</td>
<td>4.4K</td>
<td>3.8K</td>
</tr>
<tr>
<td>COIN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/13/25</td>
<td>$50.2</td>
<td>$49.6</td>
<td>$49.6</td>
<td>$295.00</td>
<td>$148.8K</td>
<td>7</td>
<td>30</td>
</tr>
<tr>
<td>COIN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$46.75</td>
<td>$45.85</td>
<td>$45.85</td>
<td>$280.00</td>
<td>$146.5K</td>
<td>460</td>
<td>5</td>
</tr>
</tbody>
</table>

<h3>About Coinbase Global</h3>
Founded in 2012, Coinbase is the leading cryptocurrency exchange platform in the United States. The company intends to be the safe and regulation-compliant point of entry for retail investors and institutions into the cryptocurrency economy. Users can establish an account directly with the firm, instead of using an intermediary, and many choose to allow Coinbase to act as a custodian for their cryptocurrency, giving the company breadth beyond that of a traditional financial exchange. While the company still generates the majority of its revenue from transaction fees charged to its retail customers, Coinbase uses internal investment and acquisitions to expand into adjacent businesses, such as prime brokerage and data analytics.
In light of the recent options history for Coinbase Global, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Coinbase Global</h3>
<ul>
<li>With a volume of 4,530,994, the price of COIN is down -0.94% at $246.5. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 62 days.</li>
</ul>
<h3>Professional Analyst Ratings for Coinbase Global</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $253.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Needham persists with their Buy rating on Coinbase Global, maintaining a target price of $270. 
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Neutral rating for Coinbase Global, targeting a price of $190. 
&#x2A; Maintaining their stance, an analyst from Oppenheimer continues to hold a Outperform rating for Coinbase Global, targeting a price of $293. 
&#x2A; An analyst from Rosenblatt has decided to maintain their Buy rating on Coinbase Global, which currently sits at a price target of $300. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Neutral rating for Coinbase Global, targeting a price of $215. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Coinbase Global options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Markets

COIN

Behind the Scenes of Coinbase Global's Latest Options Trends

Moodys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCO#NYSE">MCO</a>) has outperformed the market over the past 20 years by 4.42% on an annualized basis producing an average annual return of 12.7%. Currently, Moodys has a market capitalization of $86.27 billion. 
Buying $100 In MCO: If an investor had bought $100 of MCO stock 20 years ago, it would be worth $1,099.08 today based on a price of $479.42 for MCO at the time of writing.
<h3>Moodys's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748635812_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Moodys Stock In The Last 20 Years

VSee Health, Inc. (the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEE#NASDAQ">VSEE</a>), announced today that on May 23, 2025, the Company received a notice from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company had not yet filed its Quarterly Report on Form 10-Q for the period ended March 31, 2025, and its Annual Report on Form 10-K for the period ended December 31, 2024, the Company is not in compliance with Nasdaq's listing rule 5250(c)(1), which requires timely filing of periodic financial reports with the Securities and Exchange Commission (the "SEC").
 &nbsp;

VSEE

VSee Health Notified Of Non-Compliance Over Late SEC Filings

A storm is building in the bond market, according to JPMorgan Chase CEO Jamie Dimon who sees the financial system vulnerable to a sudden fracture fueled by years of unchecked <a href="https://www.benzinga.com/news/econ-s">debt and monetary expansion.</a>
&#8220;You&#8217;re going to see a crack in the bond market,&#8221; Dimon said, warning regulators and market participants of a looming dislocation. 
&#8220;It&#8217;s going to happen, and you&#8217;re going to panic. I&#8217;m not going to panic.&#8221;
Speaking at the Reagan National Defense Forum in Simi Valley, Dimon said that the U.S. has borrowed and spent $10 trillion since 2020. 
The Federal Reserve has added $8 trillion to its balance sheet via quantitative easing, Dimon highlighted, while global central banks added a similar amount. 
"These are very large numbers," Dimon said.
Combined, that&#8217;s $16 trillion in monetary expansion across the world. Dimon said the long-term effects of this financial deluge remain uncertain, but he is confident instability is on the horizon.
According to the Congressional Budget Office, the U.S. ran a $1.8 trillion deficit in fiscal year 2024, and the federal debt rose to $35 trillion last year. 
"When you give that kind of money to American citizens—fiscal or QE—it's like water filling every crack," Dimon said. "Some of you bought a Rolls-Royce." 
Dimon believes that asset prices remain elevated, and that a reversal could cause financial stress and strain for people. 
In his view, markets may need to suffer a shock to correct course. "Unfortunately, it may be that we need that to wake us up."
<h3 class="wp-block-heading">The Fed Is Right To Wait—For Now</h3>
Dimon expressed support for the Federal Reserve's current pause in rate cuts, saying &#8220;the Fed has a tough job&#8221; and &#8220;they were late raising rates&#8221;, but have since caught up. 
&#8220;I have enormous respect for Jay Powell,&#8221; Dimon added.
He criticized the Fed's earlier messaging, which suggested rates wouldn't rise above 2%. "We were quite prepared for rates going to 5%," he said, highlighting JPMorgan's readiness despite what he called flawed stress tests.
Yet, economic uncertainty remains. 
Looking forward, Dimon said inflation may rise again due to structural factors. "What I see is inflationary," he said, citing &#8220;huge fiscal deficits around the world&#8221;, widespread rearmament, green energy spending, and aging demographics.
He said that artificial intelligence might introduce deflationary forces, but "not next year."
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/economic-data/25/05/45697983/consumer-sentiment-stuck-at-3-year-lows-as-inflation-fears-hit-44-year-high">Consumer Sentiment Stuck At 3-Year Lows As Inflation Fears Hit 44-Year High </a></li>
</ul>
Photo: lev radin / Shutterstock.com

Econ #s

Jamie Dimon Warns Of Bond Market Crisis Caused By US Debt Binge: 'You're Going To Panic'

Contracts

CPKC Secures New 4-Year Union Contracts With Both TCRC Bargaining Units, After Arbitration

TTGT

TechTarget Receives Nasdaq Non-Compliance Notice For Delayed SEC Filings

Media giant Walt Disney Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) has launched a new perks program to reward streaming subscribers — and it involves <a href="https://www.benzinga.com/markets/cryptocurrency/23/11/35783944/disney-launches-nft-marketplace-with-dapper-labs-featuring-iconic-animation-and-star-wars-">non-fungible tokens.</a>
What Happened: Disney is launching a<a href="https://www.benzinga.com/markets/large-cap/25/05/45692478/disney-adds-fan-perks-to-win-over-us-viewers-in-streaming-battle"> new perks program</a> for Disney+ subscribers with a perks program for Hulu set to follow later in the summer.
Streaming subscribers will get discounts at select retailers and the chance to win one-of-a-kind experiences.
Subscribers are also getting access to the closed release of Disney Pinnacle by Dapper Labs, an NFT collection marketplace and platform. Subscribers will get a free monthly Mystery Capsule for an unnamed number of months.
Disney+ subscribers can also unlock a $10 Dapper Labs credit from now until June 26.
"Our fans are some of the most passionate in the world, and Perks are our way of thanking them for subscribing to Disney+," Disney+ Executive Vice President, Marketing Samantha Rosenberg said.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/22/11/29807443/nft-possibilities-for-disney-are-extraordinary-how-bob-igers-return-could-propel-web3-grow">NFT Possibilities For Disney Are &#8216;Extraordinary&#8217;: How Bob Iger&#8217;s Return Could Propel Web3 Growth</a>
Why It's Important: Dapper Labs is one of the most well-known names in the NFT space and was one of the top-valued companies in the sector with a $7.6 billion valuation<a href="https://www.benzinga.com/markets/cryptocurrency/21/09/23055933/dapper-labs-reaches-7-6b-valuation-after-250m-funding-round"> back in 2021.</a>
While buzz around NFTs has dramatically decreased, Dapper Labs has continued to launch marketplaces and NFT offerings with some of the top names in the business, including the National Basketball Association, National Football League and Disney.
Dapper Labs is the home of CryptoKitties, one of the first NFT collections; NBA Top Shot; NFL All Day and Disney Pinnacle, which launched last year. The company is also home to the Flow (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">FLOW</a>) blockchain.
Dapper CEO Roham Gharegozlou <a href="https://x.com/roham/status/1928499159793021164">called </a>Disney+ and Dapper Labs working together "a dream" on X.
Gharegozlou said he's excited to see the magic of Disney Pinnacle come to millions of additional Disney fans through the new perks program. The CEO said dropping the term NFT and using digital pins and other verbiage is important to on-board more users.
Over 50 million Disney+ users will have access to Disney Pinnacle through perks and can experience a free Mystery Capsule per month with the chance to pull rare digital pins from Disney, Pixar and Star Wars sets.
Gharegozlou said the average Disney Pinnacle user who opens one capsule goes on to rip 37 more. The Dapper CEO teases June 12 as a "another big step forward," without saying if this is for Disney Pinnacle specifically or for Dapper Labs.
The rest of the X thread talks about Dapper Labs recent growth and future plans. With the $10 Dapper Labs credit, Disney+ users could buy other NFTs from the company, like NFL and NBA digital collectibles on ALL Day and Top Shot, respectively.
While not all Disney+ subscribers will take part in this free offer, Disney may have opened the door to millions more NFT collectors for the first time.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45251203/disney-rides-strong-subscriber-growth-and-movie-hits-lifts-forecast-with-1-billion-streaming-goal">Disney Lifts Forecast With $1 Billion Streaming Goal, Abu Dhabi Park Deal And More</a></li>
</ul>
Photos: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$FLOW

Disney Offers Free NFTs To Streaming Subscribers: How 'Passionate' Fans Can Get New Digital Collectibles

Although the push for energy independence has long represented a political catalyst, it can't unilaterally save participating enterprises from turmoil. Just look at what happened to Eos Energy Enterprises Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) recently. Following an abrupt termination of a high-level executive along with an upsized convertible note offering, <a href="https://www.benzinga.com/quote/EOSE">EOSE stock</a> tumbled badly. Still, with so much bad news baked in, there could potentially be a reactionary response.
To be sure, holding any contrarian (and thus positive) view on Eos Energy symbolizes a highly risky proposition. According to a report by CFO Dive, the battery manufacturer <a href="https://www.cfodive.com/news/eos-energy-abruptly-terminates-cfo-three-months-batteries/749187/">terminated</a> CFO Eric Javidi earlier this week on Tuesday "effective immediately." Raising eyebrows — and perhaps some red flags — was that Javidi was only in the role for about three months.
Adding to the headwinds moving against EOSE stock is the latest announcement of an upsized $225 million <a href="https://www.benzinga.com/wiim/25/05/45696734/eos-energy-shares-are-trading-lower-following-an-annoucment-for-an-upsized-225-million-convertible-n">convertible note offering</a>. Such arrangements often hurt equity value due to the risk of dilution and wider investor uncertainty. Because convertible notes are debt instruments that can be <a href="https://www.benzinga.com/money/what-is-a-convertible-note">converted into equity</a>, they are liable to dilute the share pool. This is also problematic because convertible notes can usually be converted at a discount to the stock's future market price.
If that wasn't enough uncertainty, <a href="https://www.benzinga.com/quote/EOSE/insider-trades">insiders have been selling</a> EOSE stock since September 2024. To be fair, insider transactions can be difficult to interpret, particularly because there are several reasons why insiders sell their own securities — many of them mundane. Still, it's also fair to say that it's not a great look given the context.
Bears have expressed concern that Eos' projected full-year sales of about $15 million <a href="https://www.benzinga.com/quote/EOSE">fall short of prior guidance</a> of around $45 million. The miss is primarily due to supply chain delays and manufacturing difficulties, which point the finger toward execution risks.
<h2 class="wp-block-heading">A Potential Short Squeeze Adds Speculative Intrigue To EOSE Stock</h2>
To be 100% clear, no one is making the argument that EOSE stock is a compelling investment. More than enough serious concerns exist to warrant long-term skepticism. But even a sinking boat will occasionally offer air pockets that can facilitate short-term survivability. Thanks to the leverage and defined risk-reward profile of multi-leg options strategies, it may be possible to extract quick alpha.
First, EOSE stock features wildly high short interest. On March 14, the security's short interest reached 40.75% of its float. From then on, the size of the float — or the number of shares outstanding that are available for public trading — changed dramatically, thus making short interest calculations difficult. However, Fintel reports that the latest <a href="https://fintel.io/ss/us/eose">metric</a> hit 30.1%, which tracks with the historical data.
Bottom line? It's a sky-high figure, which ordinarily isn't a good sign because it means that skepticism has soared. On the other hand, if the bulls decide to pick up the discount, the bears would find themselves staring at the wrong end of the barrel. Keep in mind that in order to close a short position, bearish speculators must buy to close. Subsequently, an upswing can create a panicked positive feedback loop known as a <a href="https://www.benzinga.com/money/what-is-a-short-squeeze">short squeeze</a>.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30150737/EOSE-stock-10wk-forecast-1024x576.jpg" alt="" class="wp-image-933722" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30150737/EOSE-stock-10wk-forecast-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30150737/EOSE-stock-10wk-forecast-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30150737/EOSE-stock-10wk-forecast-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30150737/EOSE-stock-10wk-forecast.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure>
Second, market breadth data — or the study of accumulation and distribution patterns — suggest that investors could soon buy the dip in EOSE stock. Currently, the security is printing a "7-3-U" sequence: seven up weeks, three down weeks, with (surprisingly) a net positive trajectory across the 10-week period.
Notably, in 72% of cases, the following week's price action results in upside, with a median return of 12%. Should EOSE stock close the week at $4.10, there's a solid chance that it could pop to around $4.59 within a week or two.
<h2 class="wp-block-heading">Swinging For The Fences The Smart Way</h2>
With the above market intelligence, the one trade that arguably stands out the most is the 4/4.50 bull call spread expiring June 20. This transaction involves buying the $4 call and simultaneously selling the $4.50 call, for a net debit paid of $23. Should EOSE stock rise through the short strike price at expiration, the maximum reward is $27, a payout of over 117%.
There are two reasons why this idea is so tempting. First, as a baseline, EOSE stock suffers from a negative bias. On any given week, the chance that a long position will be profitable is only around 47%. Therefore, the sentiment regime inherent in the 7-3-U sequence raises the odds in favor of the bullish speculator. No guarantees exist, of course, but the shifting probabilities empirically favor a debit-based bullish strategy.
Number two, along with the higher probability of upside, the median response is usually very robust at 12%, which provides more than enough fuel for EOSE stock to hit the aforementioned short strike price. Of course, the median response also doesn't provide any certainty. However, the legitimate prospect of a short squeeze adds credibility to this forecast. The opinions and views expressed in this content are those of the individual author and do not necessarily reflect the views of Benzinga. Benzinga is not responsible for the accuracy or reliability of any information provided herein. This content is for informational purposes only and should not be misconstrued as investment advice or a recommendation to buy or sell any security. Readers are asked not to rely on the opinions or information herein, and encouraged to do their own due diligence before making investing decisions.
Read Next:
<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45687019/unh-stock-broken-contrarian-traders-eyeball-recovery">Options Corner: UnitedHealth May Be Broken But Contrarian Traders Eyeball A Recovery</a>
Photo: Shutterstock

Equities

Long Ideas

EOSE

Options Corner: EOS Energy Is A Mess But Short Squeeze Speculators Smell A 117% Payout

<a href="https://www.globenewswire.com/Tracker?data=-fS5RIVN7Jh7yEt-LO7u_rBe0HKitQ6OphG5uLNLgVTGXLP-bdI4oQ--rsz-RiHvzgtFkJ0-aLvMEP5ceW0YwIyuoDjdlSVRTQadtdK9RF8=">Kymera Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will announce results from the Phase 1 clinical trial evaluating single and multiple-ascending doses of KT-621 in healthy volunteers on Monday, June 2, 2025. The Company will host a video webcast at 8:00 a.m. ET that day.

Biotech

Events

KYMR

Kymera Therapeutics To Announce Phase 1 KT-621 Trial Results In Webcast On Monday June 2, 2025 At 8:00 am ET

In the latest quarter, 21 analysts provided ratings for Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">9</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $808.67, a high estimate of $1081.00, and a low estimate of $547.00. A 9.11% drop is evident in the current average compared to the previous average price target of $889.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1748635298_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Regeneron Pharmaceuticals among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$580.00</td>
<td>$700.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$943.00</td>
<td>$943.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$700.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$810.00</td>
<td>$940.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$940.00</td>
<td>$975.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$804.00</td>
<td>$917.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$943.00</td>
<td>$1051.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$700.00</td>
<td>$750.00</td>
</tr>
<tr>
<td>Evan David Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$800.00</td>
<td>$865.00</td>
</tr>
<tr>
<td>Trung Huynh</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$633.00</td>
<td>$768.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$587.00</td>
<td>$652.00</td>
</tr>
<tr>
<td>Hartaj Singh</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$900.00</td>
<td>$925.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$652.00</td>
<td>$759.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$975.00</td>
<td>$1004.00</td>
</tr>
<tr>
<td>John Newman</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$850.00</td>
<td>$1152.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$695.00</td>
<td>-</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$547.00</td>
<td>$575.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$917.00</td>
<td>$1019.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$1081.00</td>
<td>$1150.00</td>
</tr>
<tr>
<td>Hartaj Singh</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$925.00</td>
<td>$950.00</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$1000.00</td>
<td>$1100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Regeneron Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Regeneron Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Regeneron Pharmaceuticals's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Regeneron Pharmaceuticals's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/REGN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Regeneron Pharmaceuticals analyst ratings.</a>
<h2>About Regeneron Pharmaceuticals</h2>
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
<h3>Regeneron Pharmaceuticals: Delving into Financials</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Decline in Revenue: Over the 3M period, Regeneron Pharmaceuticals faced challenges, resulting in a decline of approximately -3.7% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Regeneron Pharmaceuticals's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 26.7%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Regeneron Pharmaceuticals's ROE excels beyond industry benchmarks, reaching 2.75%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Regeneron Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.15%, the company showcases efficient use of assets and strong financial health.
Debt Management: Regeneron Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.09.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

REGN

Forecasting The Future: 21 Analyst Projections For Regeneron Pharmaceuticals

Press Releases

Universe Pharmaceuticals INC Reports Financial Results for The First Six Months of Fiscal Year 2024

Universe Pharmaceuticals INC Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Universe Pharmaceuticals INC Announces Share Consolidation

"Cardiol Therapeutics (NASDAQ: CRDL) Heart Health Innovation – AVCO, GXAI, UPC, and More Stocks Driving Groundbreaking Advances"

Universe Pharmaceuticals INC Announces $15 Million Registered Direct Offering

Univest Securities, LLC Announces Closing of $15 Million Registered Direct Offering for its Client Universe Pharmaceuticals INC (NASDAQ: UPC)

Universe Pharmaceuticals INC Receives Nasdaq Delisting Notice Subject to Hearing Request

Universe Pharmaceuticals INC Receives Staff Determination Notice from Nasdaq Related to Delayed Annual Report

Comments

Universe Pharmaceuticals

Universe Pharmaceuticals (UPC) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル